苯磺酰胺,3-巯基-(9CI) | 171551-85-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 苯磺酰胺,3-巯基-(9CI)
• 中文别名: 3-硫基苯磺酰胺
• 英文名称: 3-Sulfanylbenzenesulfonamide
• CAS: 171551-85-2
• 化学式: C₆H₇NO₂S₂
• 分子量: 189.259
• InChiKey: AGVAPBHZZIZQRS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  69.5
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-bromo-5-phenylcyclohex-2-en-3-ol-1-one 、 苯磺酰胺,3-巯基-(9CI) 在 哌啶 作用下， 以 二氯甲烷 为溶剂， 反应 12.0h， 生成 3-(2-Hydroxy-6-oxo-4-phenylcyclohexen-1-yl)sulfanylbenzenesulfonamide
  参考文献：
  名称：

  Identification of substituted 3-hydroxy-2-mercaptocyclohex-2-enones as potent inhibitors of human lactate dehydrogenase

  摘要：

  A novel class of 3-hydroxy-2-mercaptocyclohex-2-enone-containing inhibitors of human lactate dehydrogenase (LDH) was identified through a high-throughput screening approach. Biochemical and surface plasmon resonance experiments performed with a screening hit (LDHA IC50 = 1.7 mu M) indicated that the compound specifically associated with human LDHA in a manner that required simultaneous binding of the NADH co-factor. Structural variation of this screening hit resulted in significant improvements in LDHA biochemical inhibition activity (best IC50 = 0.18 mu M). Two crystal structures of optimized compounds bound to human LDHA were obtained and explained many of the observed structure-activity relationships. In addition, an optimized inhibitor exhibited good pharmacokinetic properties after oral administration to rats (F = 45%). (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2014.06.076

文献信息

• Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof
  申请人：Enanta Pharmaceuticals, Inc.

  公开号：US10597391B2

  公开（公告）日：2020-03-24

  The present invention provides compounds of Formula I, Pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising these compounds and methods of using these compounds to prevent or treat FXR-mediated or TGR5-mediated diseases or conditions.

  本发明提供了式 I 的化合物、 其药学上可接受的盐、包含这些化合物的药物组合物以及使用这些化合物预防或治疗 FXR 介导或 TGR5 介导的疾病或病症的方法。
• WATER-SOLUBLE NEAR-INFRARED ABSORBING COLORING MATTERS AND AQUEOUS INKS CONTAINING SAME
  申请人：Hirota Koji

  公开号：US20110123784A1

  公开（公告）日：2011-05-26

  Coloring matters represented by general formula (1) or salts thereof are simply provided at a low cost as water-soluble coloring matters which exhibit absorption in the near-infrared region. Further, aqueous ink compositions which contain the coloring matters and have excellent storage stability are also provided. In general formula (1), Nc is optionally substituted naphthalocyanine; M is a metal oxide or the like; R 1 and R 2 are each independently hydrogen or the like; A is a crosslinking group; X and Y are each independently substituted arylamino or the like; k is more than 0 but up to 12 (on average); p is 0 to less than 12; the sum of k and p is more than 0 but up to 12; and any two or the three of R 1 , R 2 and A may be united to form a ring.
• UREA-CONTAINING ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF
  申请人：Enanta Pharmaceuticals, Inc.

  公开号：US20180141941A1

  公开（公告）日：2018-05-24

  The present invention provides compounds of Formula I, Pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising these compounds and methods of using these compounds to prevent or treat FXR-mediated or TGR5-mediated diseases or conditions.
• US8404036B2
  申请人：——

  公开号：US8404036B2

  公开（公告）日：2013-03-26